Novo Nordisk A/S (NVO) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 12:45 PM ET Company Participants Lars Fruergaard Jorgensen - President & Chief Executive Officer Conference Call Participants Richard Vosser - JPMorgan Richard Vosser Welcome to the Novo Nordisk session at the 2024 JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan, and it's my great pleasure to welcome the CEO of Novo, Lars Fruergaard Jorgensen to the conference for the first time. So ...

Novo Nordisk A/S (NVO) announced positive top-line results from its late-stage COMBINE 3 study evaluating once-weekly IcoSema in 679 people with type II diabetes inadequately controlled on daily basal insulin.The company’s investigational candidate, IcoSema, is a fixed-ratio combination of basal insulin icodec and semaglutide.The 52-week phase IIIa COMBINE 3 study is comparing the efficacy and safety of once-weekly IcoSema against once-daily insulin glargine U100 and insulin aspart (injected two to four tim ...

A standout stock in the healthcare sector last year, Novo Nordisk (NVO 3.87%) isn't doing too badly so far in the embryonic days of 2024. On Thursday -- yet another gloomy day for the market when the S&P 500 index dipped by 0.3% -- the drugmaker's share price closed nearly 4% higher. Sparking that upbeat investor interest was news of a pair of research collaboration deals.A pair of research collaboration dealsOn Thursday morning, Novo Nordisk divulged that it had inked new arrangements with two U.S. biotech ...

Key TakeawaysNovo Nordisk said it inked research agreements with two American biotech firms to further develop metabolic-related treatments.The pharmaceutical company is already the market leader in weight-loss drugs through its GLP-1 products including Ozempic and Wegovy.Shares of NVO stock rose more than 4% on the news of the new deals.Shares of Novo Nordisk (NVO), the market leader in weight-loss drugs, jumped more than 4% Thursday after the company said it inked research agreements with two American bio ...

Novo Nordisk NVO, +1.48% NOVO.B, +1.93% said Thursday it has entered research collaboration agreements with Omega Therapeutics Inc. OMGA, -8.08% and Cellarity on new treatments for obesity management. The Danish developer of weight-loss drugs Ozempic and Wegovy said the Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller that aims to enhance metabolic activity. The Cellarity collaboration aims to discover biological drivers of metabolic dysfunction-asso ...

Novo Nordisk (NVO) closed the most recent trading day at $103.62, moving +1.48% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.8%. On the other hand, the Dow registered a loss of 0.76%, and the technology-centric Nasdaq decreased by 1.18%.Coming into today, shares of the drugmaker had gained 2.49% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 3.4%.The investment community will be paying close attention to the ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event November 11, 2023 6:00 PM ET Company Participants Daniel Bohsen - Head of Investor Relations Martin Holst Lange - Executive Vice President, Development Robin Evers - Senior Vice President of Medical Affairs, Regulatory and Safety Conference Call Participants Richard Vosser - JPMorgan Chase & Co Emily Field - Barclays Michael Novod - Nordea Pete Verdult - Citi Seamus Fernandez - Guggenheim Securities Martin Parkhøi - SEB Pete Welford - Jefferies Michael ...

Novo Nordisk A/S (NVO) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Daniel Bohsen - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President, Commercial Strategy and Corporate Affairs Doug Langa - Executive Vice President, North America Operations Martin Holst Lange - Executive Vice President, Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Ca ...

1 Investor presentation First six months of 2023 RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk –a focused healthcare company Investor presentation First six months of 2023 2 Novo Nordisk® Investor presentation First six months of 2023 Agenda Progress on Strategic Aspirations 2025 Commercial execution Agenda Innovation and therapeutic focus Financials 3 Novo Nordisk® Investor presentation First six months of 2023 Forward-looking statements Novo Nordisk's reports filed with or furnished to the ...